About China Biologic Products (NASDAQ:CBPO)
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBPO
CUSIPN/A
Phone86-10-6598-3111
Debt
Debt-to-Equity RatioN/A
Current Ratio6.08%
Quick Ratio3.93%
Price-To-Earnings
Trailing P/E Ratio17.32
Forward P/E Ratio16.42
P/E Growth1.31
Sales & Book Value
Annual Sales$370.41 million
Price / Sales7.67
Cash Flow$4.6517 per share
Price / Cash18.43
Book Value$20.05 per share
Price / Book4.28
Profitability
EPS (Most Recent Fiscal Year)$4.95
Net Income$67.94 million
Net Margins18.34%
Return on Equity21.30%
Return on Assets18.17%
Miscellaneous
Employees1,799
Outstanding Shares33,130,000
China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions
What is China Biologic Products' stock symbol?
China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."
How were China Biologic Products' earnings last quarter?
China Biologic Products (NASDAQ:CBPO) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.89 by $0.01. The biopharmaceutical company earned $90.10 million during the quarter, compared to analysts' expectations of $85.15 million. China Biologic Products had a return on equity of 21.30% and a net margin of 18.34%. The company's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period last year, the firm earned $0.95 EPS. View China Biologic Products' Earnings History.
What price target have analysts set for CBPO?
3 brokers have issued 12 month price targets for China Biologic Products' shares. Their predictions range from $97.00 to $105.00. On average, they anticipate China Biologic Products' stock price to reach $101.00 in the next year. View Analyst Ratings for China Biologic Products.
Who are some of China Biologic Products' key competitors?
Some companies that are related to China Biologic Products include Spark Therapeutics (ONCE), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX), Cellectis (CLLS) and Adaptimmune Therapeutics (ADAP).
Who are China Biologic Products' key executives?
China Biologic Products' management team includes the folowing people:
- Mr. Xiaoying Gao, Chairman, Pres & CEO (Age 67)
- Mr. Ming Yang, Chief Financial Officer (Age 46)
- Mr. Ming Yin, Sr. Corp. VP (Age 40)
- Ms. Zhijing Liu, Corp. VP (Age 64)
- Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 53)
Has China Biologic Products been receiving favorable news coverage?
Media coverage about CBPO stock has been trending somewhat positive on Monday, according to Accern Sentiment. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. China Biologic Products earned a daily sentiment score of 0.14 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.91 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of China Biologic Products?
Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is China Biologic Products' stock price today?
One share of CBPO stock can currently be purchased for approximately $85.73.
How big of a company is China Biologic Products?
China Biologic Products has a market capitalization of $2.84 billion and generates $370.41 million in revenue each year. The biopharmaceutical company earns $67.94 million in net income (profit) each year or $4.95 on an earnings per share basis. China Biologic Products employs 1,799 workers across the globe.
How can I contact China Biologic Products?
China Biologic Products' mailing address is JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD 18TH FLOOR, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]
MarketBeat Community Rating for China Biologic Products (CBPO)
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
China Biologic Products (NASDAQ:CBPO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for China Biologic Products in the last 12 months. Their average twelve-month price target is $101.00, suggesting that the stock has a possible upside of 17.81%. The high price target for CBPO is $105.00 and the low price target for CBPO is $97.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $101.00 | $101.00 | $137.50 | $137.50 |
| Price Target Upside: | 17.81% upside | 21.57% upside | 41.69% upside | 41.69% upside |
China Biologic Products (NASDAQ:CBPO) Consensus Price Target History
China Biologic Products (NASDAQ:CBPO) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
China Biologic Products (NASDAQ:CBPO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
China Biologic Products (NASDAQ CBPO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.73%
Institutional Ownership Percentage: 58.65%
China Biologic Products (NASDAQ CBPO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/9/2017 | Zhijing Cbpo Liu | Insider | Sell | 7,500 | $116.49 | $873,675.00 | 10,969 |  |
| 3/2/2017 | Sean Shao | Director | Sell | 20,000 | $100.78 | $2,015,600.00 | 36,000 | |
| 3/1/2017 | David Gao | CEO | Sell | 116,653 | $100.63 | $11,738,791.39 | 449,396 | |
| 8/15/2016 | Ming Yang | CFO | Sell | 21,092 | $124.32 | $2,622,157.44 | 24,782 | |
| 8/15/2016 | Wenfang Liu | Director | Sell | 2,900 | $124.32 | $360,528.00 | 3,383 | |
| 8/15/2016 | Zhijing Cbpo Liu | Insider | Sell | 1,968 | $124.32 | $244,661.76 | | |
| 6/8/2016 | Wp X Biologics Llc | Director | Sell | 2,775,000 | $111.00 | $308,025,000.00 | | |
| 5/20/2016 | Ming Yang | CFO | Sell | 13,908 | $113.64 | $1,580,505.12 | 52,282 | |
| 5/20/2016 | Ming Yin | VP | Sell | 19,618 | $113.64 | $2,229,389.52 | 51,419 | |
| 3/11/2016 | Zhijing Cbpo Liu | VP | Sell | 282 | $108.00 | $30,456.00 | 718 | |
| 3/7/2016 | Wp X Biologics Llc | Director | Sell | 4,257,000 | $107.00 | $455,499,000.00 | | |
| 12/7/2015 | Zhijun Tong | Director | Sell | 15,000 | $118.33 | $1,774,950.00 | 14,000 | |
| 11/4/2015 | David Gao | CEO | Sell | 95,991 | $115.60 | $11,096,559.60 | 377,000 | |
| 11/2/2015 | David Gao | CEO | Sell | 12,891 | $112.26 | $1,447,143.66 | 472,991 | |
| 10/29/2015 | David Gao | CEO | Sell | 71,118 | $110.21 | $7,837,914.78 | 485,882 | |
| 10/26/2015 | David Gao | CEO | Sell | 59,542 | $105.22 | $6,265,009.24 | 557,000 | |
| 10/20/2015 | David Gao | CEO | Sell | 258 | $105.00 | $27,090.00 | 616,542 | |
| 10/19/2015 | David Gao | CEO | Sell | 200 | $105.03 | $21,006.00 | 616,542 | |
| 9/15/2015 | Ming Yang | CFO | Sell | 9,000 | $94.56 | $851,040.00 | 24,782 | |
| 9/15/2015 | Ming Yin | VP | Sell | 20,508 | $95.55 | $1,959,539.40 | 13,467 | |
| 9/14/2015 | Ming Yang | CFO | Sell | 11,304 | $97.08 | $1,097,392.32 | 24,782 | |
| 9/14/2015 | Wenfang Liu | Director | Sell | 2,717 | $97.02 | $263,603.34 | 3,283 | |
| 9/14/2015 | Zhijing Cbpo Liu | VP | Sell | 6,786 | $99.29 | $673,781.94 | | |
| 6/15/2015 | Wp X Biologics Llc | Director | Sell | 2,645,000 | $100.28 | $265,240,600.00 | | |
| 11/21/2014 | Zhijing Cbpo Liu | VP | Sell | 8,000 | $68.95 | $551,600.00 | | |
| 11/10/2014 | Sean Shao | Director | Sell | 72,500 | $62.75 | $4,549,375.00 | | |
| 11/10/2014 | Zhijing Cbpo Liu | VP | Sell | 7,500 | $62.75 | $470,625.00 | | |
| 9/15/2014 | Gang Cbpo Yang | VP | Sell | 2,454 | $54.00 | $132,516.00 | | |
| 9/15/2014 | Ming Yang | CFO | Sell | 6,164 | $54.00 | $332,856.00 | | |
| 9/12/2014 | Ming Yin | VP | Sell | 3,073 | $54.00 | $165,942.00 | | |
| 9/12/2013 | Wenfang Liu | Director | Sell | 2,524 | $25.00 | $63,100.00 | | |
| 5/14/2013 | Wp X Biologics Llc | Director | Buy | 3,112,920 | $20.00 | $62,258,400.00 | | |
(Data available from 1/1/2013 forward)
China Biologic Products (NASDAQ CBPO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | China Biologic Products (CBPO) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 21 at 8:42 AM |
| China Biologic Products (CBPO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 21 at 3:30 AM |
| China Biologic Products (CBPO) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 18 at 12:16 PM |
| Analysts Anticipate China Biologic Products (CBPO) Will Announce Earnings of $1.28 Per Share
www.americanbankingnews.com - April 11 at 8:43 AM |
| BidaskClub Upgrades China Biologic Products (CBPO) to "Hold"
www.americanbankingnews.com - April 7 at 7:02 AM |
| China Biologic Products Holdings, Inc. (CBPO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 27 at 3:26 AM |
| $1.28 EPS Expected for China Biologic Products Holdings, Inc. (CBPO) This Quarter
www.americanbankingnews.com - March 25 at 8:48 AM |
| China Biologic Products (CBPO) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 17 at 6:44 PM |
| China Biologic Products (CBPO) and Galmed Pharmaceuticals (GLMD) Head to Head Contrast
www.americanbankingnews.com - March 16 at 3:13 AM |
| China Biologic Products' (CBPO) "Buy" Rating Reiterated at Jefferies Group
www.americanbankingnews.com - March 15 at 12:26 PM |
| China Biologic Products Holdings, Inc. (CBPO) Expected to Post Earnings of $1.28 Per Share
www.americanbankingnews.com - March 8 at 1:08 AM |
| China Biologic Products Holdings, Inc. (CBPO) Position Lifted by Bank of New York Mellon Corp
www.americanbankingnews.com - March 6 at 4:54 AM |
| China Biologic Products (CBPO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 5 at 7:20 PM |
| China Biologic Products (CBPO) PT Set at $105.00 by Deutsche Bank
www.americanbankingnews.com - March 3 at 6:12 PM |
| China Biologic Products (CBPO) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 3 at 6:10 PM |
| China Biologic Products (CBPO) Downgraded by TheStreet
www.americanbankingnews.com - March 3 at 1:56 PM |
| China Biologic Products Holdings, Inc. (CBPO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 2 at 4:30 PM |
| China Biologic Products (CBPO) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - February 28 at 9:20 PM |
| Comerica Bank Sells 4,290 Shares of China Biologic Products Holdings, Inc. (CBPO)
www.americanbankingnews.com - February 27 at 7:14 AM |
| Analysts Anticipate China Biologic Products Holdings, Inc. (CBPO) to Announce $1.11 EPS
www.americanbankingnews.com - February 27 at 1:36 AM |
| China Biologic Products Holdings, Inc. (CBPO) Shares Sold by Schroder Investment Management Group
www.americanbankingnews.com - February 26 at 1:50 PM |
 | China Biologic Products to Report Fourth Quarter and Fiscal Year 2017 Financial Results
finance.yahoo.com - February 23 at 9:01 AM |
| China Biologic Products (CBPO) Upgraded at BidaskClub
www.americanbankingnews.com - February 19 at 3:38 PM |
| Brokerages Expect China Biologic Products Holdings, Inc. (CBPO) to Announce $1.11 Earnings Per Share
www.americanbankingnews.com - February 19 at 12:16 PM |
| China Biologic to Build New Collection Station in Hainan Province
finance.yahoo.com - February 14 at 9:26 AM |
| Zacks: Analysts Set $111.67 Target Price for China Biologic Products Holdings, Inc. (CBPO)
www.americanbankingnews.com - February 12 at 1:34 AM |
| Should You Expect China Biologic Products Holdings Inc (NASDAQ:CBPO) To Continue Delivering An ROE Of 20.70%?
finance.yahoo.com - February 9 at 4:44 PM |
| China Biologic Products (CBPO) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 5 at 7:40 PM |
| China Biologic Products (CBPO) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM |
| China Biologic Products Holdings, Inc. (CBPO) Expected to Post Earnings of $1.11 Per Share
www.americanbankingnews.com - February 2 at 2:22 PM |
| Financial Survey: Chimerix (CMRX) versus China Biologic Products (CBPO)
www.americanbankingnews.com - February 1 at 11:06 PM |
| China Biologic Products (CBPO) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 29 at 9:36 PM |
| Brokerages Expect China Biologic Products Holdings, Inc. (CBPO) to Post $1.11 Earnings Per Share
www.americanbankingnews.com - January 28 at 11:34 AM |
| Brokerages Expect China Biologic Products Holdings, Inc. (CBPO) to Announce $1.11 EPS
www.americanbankingnews.com - January 16 at 11:42 AM |
| Brokerages Anticipate China Biologic Products Holdings, Inc. (CBPO) to Post $1.11 EPS
www.americanbankingnews.com - January 14 at 12:02 AM |
| Brokerages Expect China Biologic Products Holdings, Inc. (CBPO) to Post $1.11 EPS
www.americanbankingnews.com - January 10 at 5:08 AM |
 | China Biologic Announces Corporate Update - PR Newswire (press release)
www.prnewswire.com - January 8 at 5:00 PM |
| Has China Biologic Products Holdings Inc (NASDAQ:CBPO) Improved Earnings Growth In Recent Times?
finance.yahoo.com - January 8 at 5:00 PM |
| China Biologic to Attend the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 8 at 10:11 AM |
| China Biologic Announces Corporate Update
finance.yahoo.com - January 8 at 10:11 AM |
| Analysts Anticipate China Biologic Products Holdings, Inc. (CBPO) to Announce $1.11 Earnings Per Share
www.americanbankingnews.com - January 6 at 9:56 AM |
| China Biologic Announces Completion of Acquisition of TianXinFu from PWM
finance.yahoo.com - January 3 at 9:18 AM |
| How Do Analysts See China Biologic Products Holdings Inc (NASDAQ:CBPO) Performing Over The Next Few Years?
finance.yahoo.com - January 1 at 4:50 PM |
| Analysts Expect China Biologic Products Holdings, Inc. (CBPO) Will Post Earnings of $1.11 Per Share
www.americanbankingnews.com - December 30 at 3:14 PM |
| China Biologic Products Holdings, Inc. – Value Analysis (NASDAQ:CBPO) : December 29, 2017
finance.yahoo.com - December 29 at 4:49 PM |
| China Biologic Products Holdings, Inc. breached its 50 day moving average in a Bearish Manner : CBPO-US : December 28, 2017
finance.yahoo.com - December 28 at 11:16 AM |
| China Biologic Products (CBPO) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - December 24 at 10:02 AM |
| Should You Be Tempted To Buy China Biologic Products Holdings Inc (NASDAQ:CBPO) Because Of Its PE Ratio?
finance.yahoo.com - December 22 at 7:59 PM |
| China Biologic Products Holdings, Inc. (CBPO) Given $111.67 Consensus Target Price by Brokerages
www.americanbankingnews.com - December 22 at 10:10 AM |
| China Biologic Receives Operating Permit for New Collection Facility in Ju County in Shandong Province
finance.yahoo.com - December 15 at 10:27 AM |
China Biologic Products (NASDAQ:CBPO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
China Biologic Products (NASDAQ:CBPO) Income Statement, Balance Sheet and Cash Flow Statement
China Biologic Products (NASDAQ CBPO) Stock Chart for Monday, April, 23, 2018
Loading chart…
